newsfilter
← Latest News
PR Newswire·

MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2022

HUDDINGE, Sweden, April 28, 2022 /PRNewswire/ -- Momentum in several areas, not least the development of our cutting-edge project fostroxacitabine bralpamide January – MarchFinancial summary for the quarter Net turnover amounted to SEK 0.5 (9.9)